Aspirin-exacerbated respiratory disease, commonly shortened to AERD, is a chronic inflammatory condition in which aspirin and similar pain relievers trigger respiratory reactions in people who already have asthma and nasal polyps. It affects roughly 7% of all adults with asthma, and the figure climbs to about 15% among those with severe asthma.1Journal of Allergy and Clinical Immunology. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature Despite those numbers, AERD is frequently missed or recognized years after symptoms begin. The condition sits at the intersection of allergy, pulmonology, and ear-nose-throat medicine, which partly explains why getting a straight answer about it can be so frustrating.
The Three Components and How They Unfold
AERD is sometimes still called Samter’s Triad because it has three hallmark features: asthma, nasal polyps (growths in the sinus lining), and respiratory reactions to aspirin or other COX-1-inhibiting pain relievers. These three pieces rarely show up all at once. In most people, they arrive one at a time over months or years, which is a major reason the condition goes undiagnosed for so long.
A large insurance-claims analysis found that about 59% of patients first received an asthma diagnosis, 25% were first diagnosed with nasal polyps, and 16% first learned of their drug sensitivity. The single most common sequence, seen in about 36% of cases, was asthma first, then nasal polyps, then recognition of aspirin or NSAID intolerance. Among patients whose drug sensitivity was not the first clue, the typical gap between upper or lower airway disease and confirmed drug allergy was roughly nine months.2PubMed Central. Longitudinal progression of aspirin-exacerbated respiratory disease: analysis of a national insurance claims database
A separate study of 240 patients found a median diagnostic delay of three years, and more than a quarter of patients were completely unaware of their diagnosis at the time of their initial clinic presentation. Black and Latino patients were more likely to be unaware of their diagnosis than White patients. The study also found that those whose asthma appeared first tended to develop it at a younger age (around 25, on average), while men and people with higher pollution exposure were more likely to present with NSAID sensitivity as their earliest symptom.3PubMed Central. Sex, Ethnicity, Body Mass Index, and Environmental Exposures Associated With NSAID-Exacerbated Respiratory Disease Symptom Sequence
What Is Happening Inside the Airways
The core problem in AERD is a lopsided production of certain fat-derived signaling molecules called leukotrienes and prostaglandins. In a healthy airway, these chemicals balance each other: prostaglandin E2 generally calms inflammation, while cysteinyl leukotrienes promote it. In AERD, the balance tips dramatically. The enzymes that produce cysteinyl leukotrienes are overactive, flooding the airways with inflammatory signals even before someone takes an aspirin.4PubMed Central. Factors driving the aspirin exacerbated respiratory disease phenotype At the same time, the protective prostaglandin E2 tends to run low, while a different prostaglandin (PGD2) that drives inflammation runs high.5PubMed Central. Low Prostaglandin E2 but High Prostaglandin D2, a Paradoxical Dissociation in Arachidonic Acid Metabolism in Aspirin-Exacerbated Airway Disease: Role of Airway Epithelium
When a person with AERD takes aspirin or a similar COX-1-blocking painkiller, the drug further shuts down the little remaining prostaglandin E2 production. With that brake removed, cysteinyl leukotriene levels surge. The result is a cascade of effects: mast cells and eosinophils release more inflammatory chemicals, immune cells called ILC2s are activated, and the airways respond with bronchoconstriction, swelling, mucus production, and sometimes a drop in blood pressure.6PubMed Central. Cellular interactions in aspirin-exacerbated respiratory disease Platelets that stick to white blood cells also contribute to the leukotriene overload, which helps explain why the inflammation in AERD is so persistent and hard to control with standard asthma treatments.7PubMed Central. Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes
How AERD Is Diagnosed
There is no simple blood test that confirms AERD the way a throat swab confirms strep. The gold standard remains a provocation challenge: a doctor gives the patient a controlled dose of aspirin and watches for a reaction. Oral challenges, done in a hospital setting, have historically been the most common approach. A newer alternative uses aspirin sprayed into the nose (intranasal aspirin challenge), which appears to be safer and easier to tolerate. Research on intranasal challenges found that a cumulative dose of 70 mg achieved the highest diagnostic accuracy, around 91%, with nasal congestion and runny nose as the most pronounced response. Only about 4% of participants experienced a worsening of their asthma during the test.8PubMed. Intranasal Aspirin Challenge for Diagnosis of Aspirin-Exacerbated Respiratory Disease: Symptom Score Criteria and Optimal Dosage
For patients who cannot undergo a challenge, urine testing for leukotriene E4 (a breakdown product of those overproduced cysteinyl leukotrienes) can offer a supporting clue. High levels of urinary leukotriene E4 are reliably associated with AERD: one study found that a specific threshold could identify confirmed aspirin-sensitive patients with about 92% specificity. However, the test is better at ruling AERD in than ruling it out.9PubMed Central. Diagnostic Utility of Urinary LTE4 in Asthma, Allergic Rhinitis, Chronic Rhinosinusitis, Nasal Polyps, and Aspirin Sensitivity A separate validation study confirmed that urinary leukotriene E4 can distinguish AERD patients from aspirin-tolerant asthmatics, but the sensitivity of a spot urine sample was only about 49%, meaning roughly half of patients with AERD could still have a “normal” result.10PubMed. Diagnostic Accuracy of Urinary LTE4 Measurement to Predict Aspirin-Exacerbated Respiratory Disease in Patients with Asthma In practice, this means a high result is meaningful, but a normal result does not let you off the hook. The urine test works best as a screening tool rather than a definitive answer.11PubMed. Urine Leukotriene E4: Implications as a Biomarker in Chronic Rhinosinusitis
Alcohol Reactions and Other Underappreciated Symptoms
One of the more distinctive features of AERD that patients often discover before they ever see a specialist is a strong reaction to alcoholic drinks. About three in four AERD patients get nasal congestion or a runny nose after drinking alcohol, and about half develop wheezing or shortness of breath. These reactions are not tied to one particular type of alcohol and frequently start after just a few sips.12PubMed Central. Alcohol-induced respiratory symptoms are common in patients with aspirin exacerbated respiratory disease That kind of response is far more common in AERD than in other forms of asthma or chronic sinus disease, which makes it a useful informal red flag.
Recent research has started to unravel why this happens. AERD patients appear to have lower levels of an enzyme called ALDH2 in their nasal polyp tissue, likely driven down by the same type 2 inflammation that characterizes the disease overall. Patients who experienced alcohol-triggered respiratory symptoms also had worse sinus disease, worse asthma control, and faster polyp regrowth after surgery. Encouragingly, treatment with dupilumab or daily aspirin therapy improved alcohol-related symptoms for most patients studied.13PubMed Central. Reduced aldehyde dehydrogenase 2 in respiratory tract associates with dysregulated alcohol metabolism and respiratory reactions in aspirin-exacerbated respiratory disease
Smell Loss and Its Ripple Effects
Nasal polyps in AERD tend to be aggressive and recurrent, and one of their most distressing consequences is loss of smell. In a study of AERD patients, 85% reported a diminished sense of smell or taste, and nearly a third described the severity as “as bad as it can be.” The impact goes well beyond not enjoying food. Among those with reduced smell, 86% said they could not identify spoiled food, 63% reported feeling unsafe in their daily lives, and more than half had encountered genuinely dangerous situations they could not detect by smell, like gas leaks or smoke.14PubMed Central. Loss of smell in patients with aspirin-exacerbated respiratory disease impacts mental health and quality of life
Worse smell loss was also tied to higher rates of psychological distress and more physically and mentally unhealthy days per month, even after accounting for how well a patient’s asthma was controlled. This makes olfactory dysfunction a major quality-of-life issue in AERD, one that clinicians increasingly recognize needs direct attention rather than being treated as a footnote to sinus disease.
Which Painkillers Are Safe
A common and understandable concern for people with AERD is what they can actually take for pain or fever. The core issue is COX-1 inhibition: drugs that strongly block the COX-1 enzyme are the ones that trigger reactions. That puts aspirin, ibuprofen, naproxen, and most traditional over-the-counter anti-inflammatory drugs off-limits.15Respiratory Medicine. Aspirin-exacerbated respiratory disease: An update
Acetaminophen (Tylenol) at low to moderate doses is generally tolerated, though high doses can trigger mild reactions in a small fraction of patients. Selective COX-2 inhibitors, such as celecoxib, have been studied specifically in AERD patients and show a reassuring safety profile. A meta-analysis of controlled trials found no significant increase in respiratory symptoms, lung-function drops, or nasal symptoms with COX-2 inhibitors compared to placebo.16PubMed. Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2 inhibitors: Meta-analysis of controlled clinical trials An earlier pooled analysis of 172 AERD patients found that all of them tolerated the selective COX-2 inhibitor administered without reactions.17PubMed. Safety of COX-2 inhibitors in asthma patients with aspirin hypersensitivity Weakly selective NSAIDs that fall between full COX-1 blockers and true COX-2 inhibitors are more of a gray zone: the same meta-analysis found that these triggered respiratory symptoms in roughly 1 in 13 AERD patients, so they carry real risk.
Aspirin Desensitization
It sounds paradoxical, but aspirin itself is one of the most established treatments for AERD. The procedure, called aspirin desensitization, works by gradually escalating aspirin doses under medical supervision until the patient can tolerate a full therapeutic dose. Once desensitized, patients take aspirin daily to maintain tolerance. The American Academy of Allergy, Asthma & Immunology notes that while AERD patients traditionally develop significant upper and lower respiratory symptoms when exposed to COX-1 inhibitors, most of those same patients report clinical benefit after desensitization and maintenance therapy.18PubMed Central. The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease
A retrospective comparison of postoperative treatment strategies found that aspirin desensitization and leukotriene-receptor antagonists (like montelukast) both significantly reduced nasal polyp recurrence compared to topical steroids alone when given after sinus surgery. The montelukast group showed particular improvement in subjective sinus symptoms and quality of life over time.19International Archives of Allergy and Immunology. AERD Associated Nasal Polyposis: Efficacy of Postoperative Antileukotriene Therapy in Comparison with Aspirin Desensitization Daily aspirin therapy is not without downsides, though. Gastrointestinal side effects are common, and some patients cannot sustain the regimen long-term. The rise of biologic therapies has given patients another option, and for some, a more tolerable one.
Biologics and Leukotriene Modifiers
Biologic drugs, particularly dupilumab and omalizumab, have changed the treatment landscape for AERD. A systematic review and meta-analysis covering 15 randomized controlled trials and over 800 AERD patients found that biologics produced clinically meaningful improvements in both upper-airway outcomes (polyp size, nasal congestion, sinus symptom scores, smell identification) and lower-airway outcomes (asthma control and lung function). All improvements exceeded the thresholds considered clinically meaningful, not just statistically detectable.20PubMed. Biologics and Selected Upper- and Lower-Airway Outcomes in AERD Subgroups: A Systematic Review and Meta-Analysis Separate research suggests that dupilumab and omalizumab may also reduce or eliminate aspirin reactivity itself in some patients, though these findings come from small, often uncontrolled studies.21PubMed. Biologic Therapy and Aspirin Reactivity in Aspirin-Exacerbated Respiratory Disease: A Scoping Review
Leukotriene modifiers, the oral medications montelukast and zileuton, target the overproduction of leukotrienes more directly. Zileuton blocks the enzyme that makes leukotrienes in the first place, while montelukast blocks the receptor they act on. Both are used in AERD, often as add-on therapies. In a long-term study of 40 AERD patients, those with more severe sinus disease were eventually switched from montelukast to zileuton. The switch significantly lowered the number of subsequent surgeries they needed, although improvements in symptom scores and endoscopic findings did not reach statistical significance.22PubMed. Long-term role of zileuton in the treatment of chronic rhinosinusitis in aspirin exacerbated respiratory disease A separate study found similar trends: patients on zileuton tended to need fewer revision surgeries, although other quality-of-life measures were not statistically different from those not on zileuton.23PubMed Central. Effect of Zileuton Treatment on Sinonasal Quality of Life in Patients with Aspirin-Exacerbated Respiratory Disease Zileuton requires liver monitoring and is taken multiple times a day, which limits its practical appeal for some patients.
Surgery and Polyp Recurrence
Most people with AERD will undergo sinus surgery at some point, often more than once. Endoscopic sinus surgery can dramatically improve breathing and restore some sense of smell, at least temporarily. The challenge is that AERD polyps are notorious for growing back. A study of patients who had a modified endoscopic procedure (a more extensive surgery that opens the frontal sinuses) found that polyps recurred in 58% of patients, and about 23% eventually needed another surgery.24PubMed. Outcomes of modified endoscopic Lothrop in aspirin-exacerbated respiratory disease with nasal polyposis AERD patients had a significantly higher risk of recurrence and revision surgery compared to patients with nasal polyps from other causes.
This is precisely why postoperative medical management matters so much. Surgery clears the field, but without ongoing medication, whether that is aspirin desensitization, a leukotriene modifier, a biologic, or some combination, polyps tend to return faster and more aggressively in AERD than in other forms of chronic sinusitis.
Dietary Approaches
Because AERD is driven by an imbalance in fat-derived inflammatory molecules, researchers have explored whether changing the types of fats in the diet could help. A pilot trial put AERD patients on a two-week diet low in omega-6 fatty acids (which feed the inflammatory pathways) and higher in omega-3 fatty acids. The dietary change led to a significant drop in urinary leukotriene E4 and in another inflammatory prostaglandin marker. Patients also reported meaningful improvement in their sinus symptom scores. The improvement in asthma control was statistically significant but did not clear the bar for clinical significance, and lung function itself did not change.25PubMed Central. Dietary fatty acid modification for the treatment of aspirin-exacerbated respiratory disease: A prospective pilot trial
This was a small, uncontrolled trial, so it is far from definitive. But the biological plausibility is there: if you starve the leukotriene production line of its raw materials while providing building blocks for anti-inflammatory molecules, you might nudge the balance. For patients looking for something they can control themselves alongside their medications, reducing processed seed oils and increasing fatty fish or fish oil is a low-risk experiment. It is unlikely to replace medications, but some patients find it a useful complement.
AERD During Pregnancy
Pregnancy raises a particular dilemma for patients who have been maintained on daily aspirin therapy after desensitization. Aspirin use during pregnancy carries known risks, especially in higher doses. A case report and discussion in the literature concluded that aspirin desensitization and maintenance therapy can be considered during pregnancy, but only after a careful assessment of risks and benefits alongside an obstetrician.26Annals of Allergy, Asthma & Immunology. Aspirin Desensitization in Pregnancy In practice, many specialists will transition pregnant patients to other therapies if possible. For women planning pregnancy, discussing the treatment plan well ahead of conception allows time to adjust medications safely. Low-dose aspirin is actually used in obstetrics for preeclampsia prevention, so the picture is nuanced, and each patient’s asthma severity, polyp burden, and pregnancy risk factors need to be weighed individually.
Why It Takes So Long to Get Diagnosed
Several features of AERD conspire to delay diagnosis. The three components develop sequentially rather than simultaneously, so the full picture may not exist when a patient first sees a doctor. Asthma is common, nasal polyps are common, and many patients have never knowingly taken a traditional NSAID or have not connected their congestion after a dose of ibuprofen to a drug reaction rather than a coincidence or a cold. The alcohol sensitivity that many AERD patients experience is another missed signal: patients and doctors alike tend to attribute nasal stuffiness after a glass of wine to histamine in the drink, not to an underlying inflammatory disease.
Even when all three components are present, AERD can fall through the cracks of specialty medicine. Pulmonologists manage the asthma, ear-nose-throat surgeons manage the polyps, and unless someone connects the dots, the drug sensitivity component goes unrecognized. That three-year median diagnostic delay found in study populations likely underestimates the true gap, since the clock only starts ticking from the first documented symptom, and many patients live with mild congestion or infrequent wheezing for years before seeking care. The practical lesson for patients with stubborn asthma and recurrent nasal polyps is to bring up any reactions to pain relievers or alcohol at their next appointment, even if those reactions seem minor. Connecting those dots is often what finally leads to the right diagnosis.